An injection for long-lasting HPV 16 or 18 infection
Part of Infections clinical trials.
This study tests an injection called BBM-C101 that may help the body clear a long-lasting HPV 16 or 18 infection and prevent precancerous changes from getting worse. It is for people who have not been helped by standard creams or who prefer not to have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have had a confirmed HPV 16 or 18 infection for more than a year
- Have tried a medicine like imiquimod or cidofovir gel, or chose not to have surgery
- Have a precancerous condition (no cancer) in the cervix, vulva, vagina, or anus
- Be willing to provide samples and have a normal or acceptable heart test (ECG)
- If you can become pregnant, agree to use reliable birth control during the study and for a year after
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called BBM-C101 for women with high-grade cervical precancerous lesions linked to HPV types 16 or 18. The goal is to see if it can safely help the body clear these abnormal cells and prevent them from becoming cancer.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This trial tests an experimental vaccine for women who have HPV type 16 but only mild or no precancerous changes (CIN1 or less). The vaccine uses a special device to help your body's immune system fight the virus, which may prevent it from becoming cervical cancer.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This trial tests a new drug (NWRD09) for people who have had HPV type 16 infection in the anal area for over a year. It aims to see if the drug can help clear the virus without causing serious side effects.
Hear when a new HPV16/18 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.